Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue PADP Prior Auth Policy Update | OpenP…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFlorida BluePolicy N/A

    Provider Administered Drug Program (PADP) — Prior Authorization and PADP Drug List

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the Provider Administered Drug Program (PADP) managed by Prime Therapeutics (Magellan Rx Management) for Florida Blue and Health Options, specifying which provider settings, member products, and HCPCS/J-codes require prior authorization and are managed under the program.

    Policy Summary
    PayerFlorida Blue
    PolicyProvider Administered Drug Program (PADP) — Prior Authorization and PADP Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Dateas written
    Next Review DateN/A
    Key ActionObtain prior authorization from Prime Therapeutics (Magellan Rx Management) for listed PADP HCPCS/J/Q codes before administering or billing the drugs.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    200+listed HCPCS/J-codes/drugs in this partial extract
    ~120+distinct HCPCS/J codes listed in this excerpt
    AllApplies to member benefit arrangements
    includes J9999Unclassified/NOC HCPCS referenced
    Medicare Part BExcluded from PADP management

    Coverage Criteria

    The following member products, provider types and benefit arrangements are excluded from MRxM (PADP) management: Medicare Part B Primary, FEP (Federal Employee Program), BlueCard Host, Be Healthy, Medicare Advantage HMO & PPO, Medicare Supplement, and CareCentrix providers when services are In‑State Home or Ambulatory Infusion Suite (AIS) (CareCentrix will perform prior authorization for those CareCentrix cases). In addition, drugs that are covered and processed through the Pharmacy Benefit (PBM or Part D) are not managed by MRxM. Providers participating in Florida Blue PADP should confirm whether the member’s benefit arrangement places the drug under PADP or routes prior authorization elsewhere prior to administration.

    When billing with unclassified/unspecified HCPCS, note that drugs associated to J9999 are NOT accepted with C9399. Per the PADP guidance, Magellan Rx Management (MRxM) authorizations will not be applied when claims are billed with C9399. Ensure the correct HCPCS is used—once CMS assigns a permanent HCPCS to a product it will be added to the PADP Drug List and managed through MRxM.

    HCPCS / J-code Lists

    PADP Managed HCPCS/J-codes list (partial)HCPCSCovered
    A9513LUTETIUM LU 177
    A9543IBRITUMOMAB TIUXETAN
    A9590IODINE I-131 IOBENGUANE
    A9600STRONTIUM SR-89 CHLORIDE
    A9604SAMARIUM SM-153 LEXIDRONAM
    A9606RADIUM RA223 DICHLORIDE THER
    A9607LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
    A9699UNCLASSIFIED RADIOPHARMACEUTICAL
    J0013ESKETAMINE (SPRAVATO)
    J0129ABATACEPT (ORENCIA IV)
    1–10 of 90
    1/9
    Continuation of listed HCPCS/J codesHCPCSCovered
    J1439INJECTAFER / FERRIC CARBOXYMALTOSE
    J1440REBYOTA / FECAL MICROBIOTA, LIVE-JSLM
    J1442NEUPOGEN / FILGRASTIM
    J1447GRANIX / TBO-FILGRASTIM
    J1448COSELA / TRILACICLIB
    J1449ROLVEDON / EFLAPEGRASTIM-XNST
    J1453EMEND / FOSAPREPITANT
    J1454AKYNZEO / FOSNETUPITANT & PALONOSE
    J1458NAGLAZYME / GALSULFASE
    J1459PRIVIGEN / HUMAN IMMUNE GLOBULIN
    1–10 of 30
    1/3
    HCPCS J-code list requiring prior authorizationHCPCSCovered
    J7324HIGH MOLECULAR WEIGHT HYALURONAN INJECTION
    J7325HYLAN G-F 20 (SYNVISC / SYNVISC ONE)
    J7326CROSS-LINKED HYALURONATE (GEL-ONE)
    J7327HIGH MOLECULAR WEIGHT HYALURONAN (MONOVISC)
    J7328HYALURONAN/DERIVATIVE (GEL-SYN)
    J7329HYALURONAN/DERIVATIVE (TRIVISC)
    J7331SYNOJOYNE (SYNOJOYT)
    J7332TRILURON
    J7352AFAMELANOTIDE (SCENESSE)
    J7354CANTHARIDIN (YCANTH)
    1–10 of 134
    1/14
    PADP HCPCS/J/Q Codes (excerpt)HCPCSCovered
    J9314
    J9316PHESGO; PERTUZUMAB, TRASTUZUMAB, and HYALURONIDASE-ZZXF
    J9317TRODELVY; SACITUZUMAB GOVITECAN-HZIY
    J9318ROMIDEPSIN, non-lyophilied
    J9319ISTODAX; ROMIDEPSIN, lyophilied
    J9321EPKINLY; EPCORITAMAB-BYSP
    J9322PEMETREXED
    J9323PEMETREXED
    J9324PEMYRDI RTU / PEMETREXED
    J9325IMLYGIC; TALIMOGENE LAHERPAREPVEC
    1–10 of 99
    1/10
    Temporary and newly assigned HCPCS/C/Q codes mentionedmixed
    J3590Unclassified drug/biological
    J9999Not otherwise classified drugs (J9999 used as unspecified)
    J1599Unclassified drugs — immune globulin IV referenced
    J3402New HCPCS effective 10/01/2025 referenced for remestemcel-L-RKND
    J9184Gemcitabine — new HCPCS reference (effective 01/01/2026) for AVGEMSI
    J9256Nipocalimab — new HCPCS reference (effective 01/01/2026) for IMAAVY
    J9282Mitomycin — new HCPCS reference (effective 01/01/2026) for ZUSDURI
    J9011Datopotamab deruxtecan — new HCPCS reference (effective 10/01/2025) for DATROWAY
    Q5160New Q-code referenced for bevacizumab biosimilar (effective 01/01/2026)
    Q5154New Q-code referenced for omalizumab (effective 10/01/2025)
    1–10 of 17
    1/2

    Provider Actions & Billing Rules

    Prior Authorization

    Prior Authorization Required

    Providers must obtain prior authorization for physician-administered drugs listed on the PADP Drug List (including drugs billed to unclassified/NOC HCPCS) before administration. Claims for listed HCPCS/J/Q codes submitted without required prior authorization may be denied and payment withheld; the member cannot be held responsible for charges denied due to missing authorization.

    • Prior authorization is required for all PADP-listed HCPCS/J/Q codes and associated drug products prior to service.
    • If a prior authorization is not obtained as required by the member benefit arrangement, payment for the service may be denied.
    • Providers participating in Florida Blue Utilization Management Programs (PADP) must request prior authorization through Magellan Rx Management (Prime Therapeutics Management MPS division).
    Prior Authorization

    PADP Unclassified HCPCS Drugs — Prior Authorization Required

    PADP includes a list of specifically coded HCPCS/J/Q drugs and a list of drugs currently billed to unclassified or NOC codes (for example J9999, J1599, J3590, A9699, Q9999). Prior authorization is required for both specifically listed HCPCS codes and those on the PADP Unclassified HCPCS Drug List.

    Background

    The Provider Administered Drug Program (PADP) utilization management program is intended to ensure proposed provider‑administered medications meet medical necessity under the member’s benefit plan and to manage utilization for select physician/healthcare professional administered medications. PADP has been managed by Prime Therapeutics Management (formerly Magellan Rx Management) since July 2009. Participating Florida Blue providers are required to obtain prior authorization for PADP‑listed drugs before administration; claims for PADP drugs submitted without required prior authorization may be denied and the member cannot be held responsible for denied charges.

    Definitions

    PADP / MRxM Management
    Program nameProvider Administered Drug Program (PADP) managed by Prime Therapeutics Management MPS division (formerly Magellan Rx Management / MRxM)
    Scope of managementPrior authorizations, voluntary pre-determinations (VPSS), and advanced organizational determinations (SAO) for designated provider-administered medications
    Effective sincePADP managed by Prime Therapeutics Management MPS division since July 2009
    Place of service includedOutpatient (on- & off-campus), ambulatory surgery centers, home, clinics, offices, ambulatory infusion suites, and other outpatient centers
    Who performs reviewsPrime Therapeutics Management MPS division (formerly known as Magellan Rx Management) performs PADP prior authorization reviews
    C-Codes

    Site of Care Applicability

    Prior Authorization

    Obtain PA for PADP drugs in outpatient settings

    PADP prior authorization and management apply when drugs are administered in outpatient settings (on‑ and off‑campus), ambulatory surgery centers, home, clinics, offices, ambulatory infusion suites (AIS), and other outpatient centers; ensure PA is obtained for services in these settings.

    Billing Rule

    Use C‑codes only in Hospital Outpatient when allowed

    C‑codes are only billable for the specified drug services within the Hospital Outpatient setting; other settings must bill with the corresponding unspecified drug HCPCS until CMS assigns a listed HCPCS.

    Policy Summary
    PayerFlorida Blue
    PolicyProvider Administered Drug Program (PADP) — Prior Authorization and PADP Drug List
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Dateas written
    Next Review DateN/A
    Key ActionObtain prior authorization from Prime Therapeutics (Magellan Rx Management) for listed PADP HCPCS/J/Q codes before administering or billing the drugs.
    SourceLink
    On This Page
    Coverage CriteriaHCPCS / J-code ListsProvider Actions & Billing RulesBackgroundDefinitionsSite of Care Applicability
    • Unclassified/NOC codes on the PADP Unclassified HCPCS Drug List (e.g., J9999, J3590, J1599) require prior authorization effective on the PADP effective dates shown.
    • The PADP Unclassified HCPCS Drug List includes the drug name, generic/description, and PADP effective date for each entry.
    Documentation Required

    Documentation Expectations for Prior Authorization

    Document clinical rationale and supporting medical records when submitting prior authorization requests. Include diagnosis, prior treatments, relevant labs/imaging, and planned administration details (dose, frequency, place of service).

    • Documentation supporting medical necessity must be available for review and may be required to complete the PADP prior authorization.
    • When member product requires a specialist referral or home nursing prior authorization, these are reviewed separately by Florida Blue per normal processes.
    Billing Rule

    Unclassified HCPCS / HCPCS Assignment & Billing Guidance

    Billing and coding guidance for NOC/unclassified and newly assigned HCPCS: continue to bill using the applicable unclassified/NOC HCPCS (J9999, J1599, J3590, A9699, etc.) for products not yet assigned a permanent HCPCS. Once CMS assigns a permanent HCPCS to a drug previously billed to an unspecified/NOC code, the new HCPCS will be included in the PADP Drug List and managed by Magellan Rx Management.

    • Do not bill drugs associated to J9999 with C9399; MRxM authorizations will not be applied when billing C9399.
    • C-codes are billable only in the Hospital Outpatient setting for specified drugs; other settings must use the unspecified drug HCPCS until a permanent HCPCS is assigned by CMS.
    • When a new permanent HCPCS is assigned, the permanent code will be added to the PADP Drug List and prior authorization requirements will follow that listing.
    Note

    Benefit-Arrangement Based Requirements

    Prior authorization requirements depend on the member benefit arrangement and provider contract. Some member products require prior authorization for PADP drugs (see PADP member benefit lists); others may be eligible for a Voluntary Predetermination of Select Services (VPSS). Verify the member's product and applicable provider arrangement before administering drugs.

    • Member benefit arrangements that require prior authorization include BlueCare HMO, SimplyBlue, My Blue (prior auth in addition to referral when applicable), BlueSelect, BlueOptions ACA/CE, and BlueChoice where applicable.
    • If a provider contract or member arrangement does not require prior authorization, providers may request a VPSS for PADP drugs; VPSS reviews for PADP drugs are performed by Prime Therapeutics Management MPS division.
    • A separate authorization for administration/per diem services is not required when the member product requires prior authorization for the drug unless specifically identified.
    DefinitionC-codes: procedure codes that are limited to specific drug services in the Hospital Outpatient setting
    Billing limitationC-Codes are only billable for the specified drug services within the Hospital Outpatient setting
    Alternate billingAll other settings must bill with the corresponding unspecified drug HCPCS until a listed HCPCS is assigned by CMS
    Post-assignment handlingOnce a drug is assigned a permanent HCPCS (including C- or Q-codes), the new HCPCS will be included in the PADP Drug List and managed through MRxM
    Unclassified HCPCS (J9999/J3590) guidance
    Use of unspecified J-codesUnspecified J-codes (e.g., J9999, J3590, J1599) are used until CMS assigns a permanent HCPCS
    Transition to permanent codesOnce CMS assigns a permanent HCPCS (including Q- and C-codes), the permanent code will be included in the PADP Drug List and managed through MRxM
    Billing restriction for C9399Drugs associated to J9999 are NOT accepted with C9399; MRxM authorizations will not be applied when billing C9399
    PADP handling for new-to-market drugsNew-to-market drugs initially listed under unclassified NOC codes will be included in PADP and require prior authorization until a permanent HCPCS is assigned